# Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
Canonical URL: https://biopharmsignal.com/news/BLTE/belite-bio-announces-availability-of-annual-report-on-form-20-f-through-company--9dcb57e9
Ticker: BLTE
Company: Belite Bio
Source: Belite Bio
Published: 2026-03-31 12:00 EST
## Summary

Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage development company focused on advancing novel...

## Article Body
Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its annual report on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2025, as filed with the Securities and Exchange Commission on March 31, 2026, is available through its website ( https:// www.belitebio.com ). Shareholders may receive a hard copy of the annual report free of charge upon request. This press release is being issued pursuant to Nasdaq Listing Rule 5250(d)(1)(C).

About Belite Bio

Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio’s lead candidate, tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye. The Company has completed a Phase 3 trial (DRAGON) in adolescent STGD1 subjects and is currently being evaluated in a Phase 2/3 trial (DRAGON II) in adolescent STGD1 subjects and a Phase 3 trial (PHOENIX) in subjects with GA. For more information, follow us on X , Instagram , LinkedIn , and Facebook , or visit us at www.belitebio.com .

Media and Investor Relations Contact:

Jennifer Wu ir@belitebio.com Julie Fallon belite@argotpartners.com
## Recent Company News
- 2026-07-20 12:00 EST — [Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1](https://biopharmsignal.com/news/BLTE/belite-bio-announces-oral-presentation-at-the-asrs-annual-meeting-featuring-addi-54caf9d6) — Source: Belite Bio
- 2026-07-15 12:00 EST — [Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference](https://biopharmsignal.com/news/BLTE/belite-bio-to-participate-in-the-h-c-wainwright-6th-annual-ophthalmology-virtual-ac101a6e) — Source: Belite Bio
- 2026-07-06 12:00 EST — [Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium](https://biopharmsignal.com/news/BLTE/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-investor-sy-df1f51d3) — Source: Belite Bio
- 2026-07-06 11:00 EST — [Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences](https://biopharmsignal.com/news/BLTE/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-59165567) — Source: Belite Bio
- 2026-06-13 01:30 EST — [Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1](https://biopharmsignal.com/news/BLTE/belite-bio-completes-rolling-submission-of-new-drug-application-to-u-s-food-and--156ed1a0) — Source: Belite Bio
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)